Marie F Demierre

Summary

Affiliation: Boston University School of Medicine
Country: USA

Publications

  1. ncbi Cutaneous melanoma: pathogenesis and rationale for chemoprevention
    Marie France Demierre
    Department of Dermatology, Skin Oncology Program, Boston University School of Medicine, Boston Medical Center, 720 Harrison Ave DOB 801A, Boston, MA 02118, USA
    Crit Rev Oncol Hematol 53:225-39. 2005
  2. ncbi Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Cancer 107:2504-11. 2006
  3. ncbi State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer
    Marie-France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    Cancer 113:1728-43. 2008
  4. ncbi Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma
    Marie France Demierre
    Department of Dermatology and Medicine, Boston University School of Medicine, 720 Harrison Avenue, DOB 801A, Boston, MA 02118, USA
    Hematol Oncol Clin North Am 17:1485-507. 2003
  5. ncbi Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    Arch Dermatol 141:325-30. 2005
  6. ncbi Chemoprevention of melanoma
    Marie France Demierre
    Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, 720 Harrison Avenue, DOB 801A, Boston, MA 02118, USA
    Curr Oncol Rep 6:406-13. 2004
  7. ncbi Early detection of thick melanomas in the United States: beware of the nodular subtype
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    Arch Dermatol 141:745-50. 2005
  8. ncbi Primary cutaneous B-cell lymphomas: a practical approach
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, 609 Albany Street, Boston, MA 02118, USA
    Hematol Oncol Clin North Am 17:1333-50. 2003
  9. ncbi Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides
    Marie France Demierre
    Skin Oncology Program, Department of Dermatology, Boston Medical Center, Boston University School of Medicine, 720 Harrison Avenue, Doctors Office Building 801A, Boston, MA 02118, USA
    Arch Dermatol 139:624-8. 2003
  10. ncbi Chemoprevention of melanoma: theoretical and practical considerations
    Marie F Demierre
    Department of Dermatology, Boston University School of Medicine, MA 02118, USA
    Cancer Control 12:219-22. 2005

Detail Information

Publications42

  1. ncbi Cutaneous melanoma: pathogenesis and rationale for chemoprevention
    Marie France Demierre
    Department of Dermatology, Skin Oncology Program, Boston University School of Medicine, Boston Medical Center, 720 Harrison Ave DOB 801A, Boston, MA 02118, USA
    Crit Rev Oncol Hematol 53:225-39. 2005
    ..To discuss potential candidate chemoprevention agents with an emphasis on the lipid lowering drugs, the statins, currently, the most promising agents...
  2. ncbi Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    Cancer 107:2504-11. 2006
    ..The authors evaluated patients' perspectives on the impact of CTCL on physical functioning, lifestyle, emotional well being, and satisfaction with treatment...
  3. ncbi State of the science 60th anniversary review: 60 Years of advances in cutaneous melanoma epidemiology, diagnosis, and treatment, as reported in the journal Cancer
    Marie-France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts, USA
    Cancer 113:1728-43. 2008
  4. ncbi Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma
    Marie France Demierre
    Department of Dermatology and Medicine, Boston University School of Medicine, 720 Harrison Avenue, DOB 801A, Boston, MA 02118, USA
    Hematol Oncol Clin North Am 17:1485-507. 2003
    ..Nevertheless, physicians who are caring for patients who have advanced MF/SS should acknowledge the spiritual dimension as an integral component of the dying process...
  5. ncbi Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    Arch Dermatol 141:325-30. 2005
    ..To measure and evaluate the health-related quality of life (HRQOL) in patients with cutaneous T-cell lymphoma (CTCL), a visible cutaneous malignancy that may have a profound effect on patients' lives...
  6. ncbi Chemoprevention of melanoma
    Marie France Demierre
    Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, 720 Harrison Avenue, DOB 801A, Boston, MA 02118, USA
    Curr Oncol Rep 6:406-13. 2004
    ....
  7. ncbi Early detection of thick melanomas in the United States: beware of the nodular subtype
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, Boston, MA 02118, USA
    Arch Dermatol 141:745-50. 2005
    ..We determined trends in distribution of thin and thick melanoma, with emphasis on the histopathologic subtype nodular melanoma...
  8. ncbi Primary cutaneous B-cell lymphomas: a practical approach
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, 609 Albany Street, Boston, MA 02118, USA
    Hematol Oncol Clin North Am 17:1333-50. 2003
    ..Several therapeutic options that are aimed at cure, are available. In most instances, chemotherapy should not be the first line of treatment...
  9. ncbi Phase 1/2 pilot study of methotrexate-laurocapram topical gel for the treatment of patients with early-stage mycosis fungoides
    Marie France Demierre
    Skin Oncology Program, Department of Dermatology, Boston Medical Center, Boston University School of Medicine, 720 Harrison Avenue, Doctors Office Building 801A, Boston, MA 02118, USA
    Arch Dermatol 139:624-8. 2003
    ....
  10. ncbi Chemoprevention of melanoma: theoretical and practical considerations
    Marie F Demierre
    Department of Dermatology, Boston University School of Medicine, MA 02118, USA
    Cancer Control 12:219-22. 2005
    ..Chemoprevention refers to the use of agents to reverse, suppress, or prevent carcinogenic progression of cancer. The use of chemoprevention is an unexplored strategy in melanoma prevention...
  11. ncbi Chemoprevention of melanoma: an unexplored strategy
    Marie France Demierre
    Boston University School of Medicine, Boston, MA, USA
    J Clin Oncol 21:158-65. 2003
    ..Possible mechanisms and molecular targets for the chemoprevention of UV-induced melanoma are discussed. This recent information should stimulate research in the chemoprevention of melanoma...
  12. ncbi What about chemoprevention for melanoma?
    Marie France Demierre
    Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, MA 02118, USA
    Curr Opin Oncol 18:180-4. 2006
    ..This paper aims to critically review the potential for a chemoprevention strategy in melanoma, and to discuss new data on candidate chemoprevention agents, as chemoprevention has been suggested as an unexplored approach in melanoma...
  13. ncbi Epidemiology and prevention of cutaneous melanoma
    Marie France Demierre
    Skin Oncology Program, Boston Medical Center, 720 Harrison Avenue DOB 801A, Boston, MA 02118, USA
    Curr Treat Options Oncol 7:181-6. 2006
    ..Chemoprevention research in melanoma should become a research priority to complement ongoing prevention strategies...
  14. ncbi Transformation in mycosis fungoides: the role of methotrexate
    Jasmin Abd-el-Baki
    Department of Dermatology, Boston University School of Medicine, 720 Harrison Avenue, Boston, MA 02118, USA
    J Cutan Med Surg 6:109-16. 2002
    ..In light of the small sample size, short followup of patients, and the inherent tendency of mycosis fungoides to transform, the role for MTX in transformation is unproven and needs to be confirmed in a multicenter study...
  15. ncbi Screening, early detection, and trends for melanoma: current status (2000-2006) and future directions
    Alan C Geller
    Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts 02118, USA
    J Am Acad Dermatol 57:555-72; quiz 573-6. 2007
    ....
  16. ncbi Statins and cancer prevention
    Marie-France Demierre
    Department of Dermatology, Boston University School of Medicine, 720 Harrison Avenue DOB 801A, Boston, MA 02118, USA
    Nat Rev Cancer 5:930-42. 2005
    ..This understanding might also help the development of drugs for other ageing-related diseases with interrelated molecular pathways...
  17. ncbi Consideration of statins for chemoprevention of cutaneous melanoma
    Marie-France Demierre
    Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, USA
    J Drugs Dermatol 4:125-8. 2005
    ....
  18. ncbi New treatments for melanoma
    Marie-France Demierre
    Department of Dermatology, Boston University School ofMedicine, Boston, MA, USA
    Dermatol Nurs 17:287-95. 2005
  19. ncbi Should the skin cancer examination be taught in medical school?
    Alan C Geller
    Department of Dermatology, Boston University School of Medicine, 720 Harrison Ave, DOB801A, Boston, MA 02118, USA
    Arch Dermatol 138:1201-3. 2002
    ..We documented the antecedents of physician practice by evaluating medical students' observation, training, performance, and self-reported skill level for the skin cancer examination and sun protection counseling...
  20. ncbi Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices
    Megan Noe
    Tufts University School of Medicine, Boston, MA, USA
    Cancer Causes Control 19:1-12. 2008
    ..This review should serve as a guide for physicians and cancer control planners when advising their patients and the public regarding screening decisions...
  21. ncbi The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999
    Alan C Geller
    Department of Dermatology, Boston University School of Medicine, Massachusetts 02118, USA
    J Am Acad Dermatol 48:34-41. 2003
    ..The purpose of this analysis is to investigate the risk factors, access to dermatologic services, and screening results of participants in AAD-sponsored programs during the first 15 years that this service was available to the US public...
  22. ncbi Macrophage-rich epithelioid angiosarcoma mimicking malignant melanoma
    Lori A Brightman
    Department of Dermatology, Boston University Medical School and Boston University Medical Center, Boston, MA 02118, USA
    J Cutan Pathol 33:38-42. 2006
    ..CONCLUSIONS: Macrophage-rich epithelioid angiosarcoma demonstrates abundant S-100 protein-positive epithelioid macrophages. This subset of epithelioid angiosarcoma may mimic malignant melanoma and may present as a pitfall in diagnosis...
  23. ncbi What's your assessment? Primary melanoma arising in association with a blue nevus
    Jason Sack
    Department of Dermatology, Boston University Medical Center, Boston, MA, USA
    Dermatol Nurs 20:113. 2008
  24. ncbi Sentinel lymph node biopsy for a squamoid eccrine carcinoma with lymphatic invasion
    Daniel I Wasserman
    Department of Dermatology, Boston University Medical Center, Boston, Massachusetts, USA
    Dermatol Surg 33:1126-9. 2007
  25. ncbi Case reports: nodular vasculitis responsive to mycophenolate mofetil
    Josephine A Taverna
    Skin Oncology Fellow, Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, MA 02118, USA
    J Drugs Dermatol 5:992-3. 2006
    ..We report a case of nodular vasculitis responsive to mycophenolate mofetil. The clinical presentation, etiology, and management options for nodular vasculitis are discussed...
  26. ncbi Well-differentiated angiosarcoma of the scalp: an unusual clinical presentation
    Anne M Chapas
    Departments of Dermatology, Boston University School of Medicine, MA 02118, USA
    J Am Acad Dermatol 52:58-9. 2005
  27. ncbi Progression of classic Kaposi's sarcoma with rituximab
    Keri S Clifford
    Department of Dermatology, Boston University School of Medicine, Boston, MA, USA
    J Am Acad Dermatol 53:155-7. 2005
    ..Dermatologists should use caution when offering rituximab for off-label use...
  28. ncbi Maternal/female caregiver influences on adolescent indoor tanning
    Jo Ellen Stryker
    Dana Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts, USA
    J Adolesc Health 35:528.e1-9. 2004
    ....
  29. ncbi Melanoma incidence and mortality among US whites, 1969-1999
    Alan C Geller
    JAMA 288:1719-20. 2002
  30. ncbi Measuring HRQOL in patients with cutaneous T-cell lymphoma undergoing therapy with oral bexarotene and extracorporeal photopheresis
    Marie-France Demierre
    Arch Dermatol 143:659-61. 2007
  31. ncbi Targeting events in melanoma carcinogenesis for the prevention of melanoma
    Christopher D Lao
    University of Michigan, 1500 East Medical Center DriveAnn Arbor, MI 48109 0848, USA
    Expert Rev Anticancer Ther 6:1559-68. 2006
    ..We will review the data for several promising agents, including statins, curcumin, resveratrol, silymarin and green tea, and discuss some importance issues and concepts that should be considered in any melanoma chemoprevention strategy...
  32. ncbi Thin melanomas and regression, thick melanomas and older men: prognostic implications and perspectives on secondary prevention
    Marie-France Demierre
    Arch Dermatol 138:678-82. 2002
  33. ncbi Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma
    David J Straus
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 109:1799-803. 2007
    ....
  34. ncbi Mirtazapine and gabapentin for reducing pruritus in cutaneous T-cell lymphoma
    Marie-France Demierre
    J Am Acad Dermatol 55:543-4. 2006
  35. ncbi Adult cutaneous Langerhans cell histiocytosis responsive to topical imiquimod
    Josephine A Taverna
    J Am Acad Dermatol 54:911-3. 2006
  36. ncbi A call for the development and implementation of a targeted national melanoma screening program
    Alan C Geller
    Arch Dermatol 142:504-7. 2006
  37. ncbi Time for the national legislation of indoor tanning to protect minors
    Marie-France Demierre
    Arch Dermatol 139:520-4. 2003
  38. ncbi Frontiers in cancer prevention research
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA
    Cancer Res 63:5649-55. 2003
  39. ncbi Thalidomide in mycosis fungoides
    Lori Brightman
    J Am Acad Dermatol 52:1100-1. 2005
  40. ncbi Characteristics associated with use or intention to use indoor tanning among adolescents
    DeAnn Lazovich
    Division of Epidemiology, University of Minnesota Minneapolis St Paul, 1300 S 2nd Street, Minneapolis, MN 55454, USA
    Arch Pediatr Adolesc Med 158:918-24. 2004
    ..Indoor tanning is a popular behavior that may increase skin cancer risk...
  41. ncbi Compliance with restrictions on sale of indoor tanning sessions to youth in Minnesota and Massachusetts
    Jean L Forster
    Division of Epidemiology and Community Health University of Minnesota, Minneapolis, MN 55454, USA
    J Am Acad Dermatol 55:962-7. 2006
    ..Minnesota and Massachusetts require parental permission, for persons younger than 16 or 18 years of age, respectively, for indoor tanning...